MotherToBaby

Medications and More during pregnancy and breastfeeding

866.626.6847

Mesalamine

Selected References:

  • Allocca M, Gilardi D, Fiorino G, Furfaro F, Peyrin-Biroulet L, Danese S. Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol. 2018;30(3):316-322.
  • Ban L et al. 2014. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology 146 (1):76-84.
  • Banerjee, A et al. (2019). Inflammatory Bowel Disease Therapies Adversely Affect Fertility in Men- A Systematic Review and Meta-analysis. Endocrine, metabolic & immune disorders drug targets, 19(7), 959–974.
  • Chermesh I & Eliakim R. 2004. Mesalazine-induced reversible infertility in a young male. Dig Liver Dis 36:551-2.
  • Watanabe, C. et al (2020). Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. Digestive diseases and sciences, 10.1007/s10620-020-06221-6. Advance online publication.
  • Colombel J-F et al. 1994. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet 344(8922):620-621.
  • Diav-Citrin O, et al. 1998. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology; 114:23-28. Ek S, Rosenborg S. 2017. Mesalazine as a cause of fetal anemia and hydrops fetalis: A case report. Medicine (Baltimore) 96(50): e9277.
  • Gaidos, J., & Kane, S. V. (2020). Medication Adherence During Pregnancy in IBD: Compliance Avoids Complications. Digestive diseases and sciences, 10.1007/s10620-020-06271-w. Advance online publication.
  • Hosseini-Carroll P et al. Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management. World J Gastrointest Pharmacol Ther. 2015;6(4):156-171.
  • Källén B. 2014. Maternal use of 5-aminosalicylates in early pregnancy and congenital malformation risk in the offspring. Scand J Gastroenterol; 49(4):442-8.
  • Mahadevan U, Matro R. Care of the pregnant patient with inflammatory bowel disease. Obstet Gynecol. 2015;126:401-12.
  • Maliszewska, A. M., Warska, A., Cendrowski, K., & Sawicki, W. (2017). Inflammatory bowel disease and pregnancy. Ginekologia Polska, 88(7), 398-403.
  • Marteau P & Devaux CB. 1994. Mesalazine during pregnancy. Lancet 344(8938):1708-1709.
  • Moskovitz DN, et al. 2004. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99(4):656-661.
  • Nelis GF. 1989. Diarrhoea due to 5-aminosalicylic acid in breastmilk. Lancet 1:383.
  • Nielsen OH et al. 2014 IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol.;11(2):116-127.
  • Norgård, B et al. (2003). Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut, 52(2), 243–247.
  • Pervez, H., Usman, N., Ahmed, M. M., & Hashmi, M. S. (2019). The Impact of Inflammatory Bowel Disease on Pregnancy and the Fetus: A Literature Review. Cureus, 11(9), e5648. https://doi.org/10.7759/cureus.5648
  • Shin T et al. 2014. Inflammatory bowel disease in subfertile men and the effect of mesalazine on fertility. Syst Biol Reprod Med 60(6); 373-376.
  • Silverman DA et al. 2005. Is mesalazine really safe for use in breastfeeding mothers? Gut 54: 170-1.
  • Xu YL, et al. 2017. Inflammatory bowel disease in pregnancy: A report of 7 cases and review of the literature. Int J Clin Exp Med; 10:5525-32.